Hans-Peter Kiem, M.D., Ph.D.

Dr. Hans-Peter Kiem currently serves as an MPM BioImpact Advisor. Dr. Kiem is an expert in stem cell biology, transplantation and gene therapy. His focus has been the development of improved hematopoietic stem cell (HSC) gene therapy and genome editing approaches for the treatment of patients with genetic and infectious diseases or cancer. His lab has described a refined HSC population for improved HSC engineering and targeting. A major recent focus has also been the development of in vivo gene therapy using various delivery platforms including viral vectors and nanoformulations to make HSC gene therapy and gene editing more portable and more widely accessible also in low and middle income countries and setting where HIV and hemoglobinopathies are most prevalent.

Dr. Kiem has had continuous NIH funding for the past 25 years and has published more than 300 manuscripts, mostly in the area of HSC biology/transplantation and gene therapy.  Dr. Kiem was the inaugural recipient of the José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research at Fred Hutchinson Cancer Center from 2009 to 2014 and now holds the Stephanus Family Endowed Chair for Cell and Gene Therapy. He is the Deputy Director of the Translational Science and Therapeutics Division and Director of the Stem Cell and Gene Therapy Program. He is also a Professor of Medicine and Pathology at the University of Washington. He served on the American Society for Gene and Cell Therapy (ASGCT) and American Society of Hematology (ASH) Stem Cell committees, and also chaired them in 2016/17. In recent years, he served on the ASGCT Board and Executive Committee and served as President of ASGCT from 2022-2023. Dr. Kiem has also been an advisor to and been involved in founding companies in the stem cell transplant and gene therapy spaces.